El interés en corto de InMed Pharmaceuticals da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de InMed Pharmaceuticals. Los datos de interés en corto se actualizan cada dos semanas.

InMed Pharmaceuticals (NASDAQ:INM) Bolsa, Informe de interés en corto

InMed Pharmaceuticals

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANAB

ASST

CCLD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DWTX

HSDT

HUBC

LSTA

NEHC

NFLX

SEPN

STFS

USEG

Netflix sorprende con un aumento en suscriptores y mejores pronósticos. Descubre también los mayores ganadores y perdedores del premercado.

Acciones de Netflix se disparan alrededor del 15%; 20 acciones que se están moviendo en el premercado de EE.UU.

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals Inc

INmune Bio Inc

InMode Ltd

Inca Minerals Ltd

iShares Intermediate Muni Income Active ETF

WIIM

Eversource Energy shares are trading lower after Barclays cut its price target on the stock from $72 to $69.

<p><strong>Clean Harbors's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLH#NYSE">CLH</a>) short percent of float has fallen 8.55% since its last report. The company recently reported that it has <strong>540 thousand shares sold short</strong>, which is 1.07% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.71 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Clean Harbors Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737573323_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Clean Harbors has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Clean Harbors's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Clean Harbors's peer group average for short interest as a percentage of float is 3.49%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

(CLH) - Analyzing Clean Harbors's Short Interest

<p><strong>ADMA Biologics's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NYSE">ADMA</a>) short percent of float has risen 11.89% since its last report. The company recently reported that it has <strong>13.62 million shares sold short</strong>, which is 5.93% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 5.97 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>ADMA Biologics Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737573317_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for ADMA Biologics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing ADMA Biologics's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ADMA Biologics's peer group average for short interest as a percentage of float is 13.65%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


ADMA

Peering Into ADMA Biologics's Recent Short Interest

<p><strong>Energy Transfer's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) short percent of float has fallen 15.69% since its last report. The company recently reported that it has <strong>39.74 million shares sold short</strong>, which is 1.29% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.94 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Energy Transfer Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737573312_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Energy Transfer has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Energy Transfer's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Energy Transfer's peer group average for short interest as a percentage of float is 4.36%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


How Is The Market Feeling About Energy Transfer?

COHR

Coherent shares are trading higher after the company announced new pin-hole array biochips for medical diagnostics with a focus on gene sequencing applications.

TE Connectivity shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

<p><strong>American Airlines Group Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) is releasing its fourth-quarter earnings on Thursday. Wall Street expects 64 cents in EPS and $13.40 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=AAL" target="_blank" rel="noreferrer noopener"> before market hours</a>.</p>
<p>The stock is up 36.01% over the past year, 8.97% YTD.</p>
<p>Let&#8217;s look at what the charts indicate for American Airlines stock and how the stock currently maps against Wall Street estimates.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/25/01/43054975/this-american-airlines-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-friday">This American Airlines Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday</a></strong></p>
<h1 class="wp-block-heading"><strong>American Airlines Stock Chart Strongly Bullish Ahead of Q4 Earnings</strong></h1>
<p>American Airlines stock is exhibiting strong bullish momentum, with its share price consistently trading above key moving averages.</p>
<p><figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="638" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22123518/Screenshot-2025-01-22-at-11.04.34-PM.png" alt="" class="wp-image-745227" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22123518/Screenshot-2025-01-22-at-11.04.34-PM.png 638w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22123518/Screenshot-2025-01-22-at-11.04.34-PM-300x232.png 300w" sizes="(max-width: 638px) 100vw, 638px" /></a></figure></p>
<p><em><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a></em></p>
<p>At $18.53, American Airlines stock remains above its 5-, 20- and 50-day exponential moving averages, indicating sustained buying pressure. The stock's position above its eight-day simple moving average (SMA) of $18.25 and 20-day SMA of $17.70 suggests continued short-term strength, potentially attracting momentum traders looking for further upside.</p>
<p>From a broader perspective, American Airlines stock significantly outpaces its 50-day SMA of $16.28 and 200-day SMA of $13.00, reinforcing a strong uptrend. This could signal confidence among investors that American Airlines is gaining stability, possibly due to improved sector fundamentals or company-specific catalysts.</p>
<p>Additionally, the MACD (moving average convergence/divergence) indicator at 0.61 aligns with the bullish trend, reflecting strengthening momentum. However, with an RSI (relative strength index) of 65.11, American Airlines stock is approaching overbought conditions, which may indicate a short-term pullback or consolidation before another leg higher.</p>
<p>For investors, these technical signals suggest that American Airlines stock remains on an upward trajectory, but risk management is key. Traders may look for dips as entry points, while longer-term investors could interpret the bullish setup as a sign of improving sentiment around the airline industry.</p>
<p>With American Airlines stock nearing overbought levels, watching for potential resistance or shifts in volume could help navigate the next moves effectively.</p>
<h1 class="wp-block-heading"><strong>American Airlines Analysts See 8% Upside</strong></h1>
<p><strong>Ratings &amp; Consensus Estimates:</strong><a href="https://www.benzinga.com/quote/AAL/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on American Airlines stock stands at a Buy currently with a price target of $18.47. The latest analyst ratings from BofA, Susquehanna and Jefferies imply an 8.2% upside for American Airlines stock.</p>
<p><strong>AAL</strong> <strong>Price Action: </strong>American Airlines stock was trading up 6.22% $18.52 at the time of publication Wednesday.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/travel/25/01/43062173/bank-of-america-delta-united-to-lead-airline-industry-in-2025">Bank Of America: Delta, United To Lead Airline Industry In 2025</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Technicals

Previews

Travel

General

American Airlines Charts Are Bullish: Can Q4 Earnings Keep The Altitude?

Teladyne Technologies shares are trading higher after the company reported better-than-expected Q4 financial results.

<p><strong>Cantor Fitzgerald</strong> analyst C.J. Muse expressed views on <strong>Seagate Technology Holdings PLC</strong>&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) second-quarter&nbsp;results while retaining a Neutral rating and<a target="_blank" href="https://www.benzinga.com/quote/stx/analyst-ratings" rel="noreferrer noopener"> a price target of $120</a>.</p>
<p>Yesterday, the company reported&nbsp;second-quarter&nbsp;FY25 revenue of&nbsp;$2.33 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43113660/seagate-technology-reports-fiscal-second-quarter-2025-financial-results" rel="noreferrer noopener">beating the consensus.</a></p>
<p>Seagate <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">expects&nbsp;third-quarter</a>&nbsp;adjusted EPS of&nbsp;$1.70 at the midpoint, against the analyst&#8217;s previewed estimate of ~$1.60. It also expects revenue of&nbsp;$2.10&nbsp;billion at the midpoint versus the&nbsp;analyst&#8217;s previewed estimate of $2.10 billion.</p>
<p>The analyst says Seagate provided a better-than-expected report, with March quarter revenues down $200 million due to previously discussed supply chain issues.</p>
<p>Muse writes that while some investors fear a cyclical peak after six quarters of Nearline revenue recovery, management highlighted limited supply additions, build-to-order contracts, long lead times of up to 52 weeks, and strong AI-driven EB growth, supporting sustained demand.</p>
<p>The analyst notes that management remains highly optimistic about the HAMR ramp in the second half of FY25, expecting it to drive incremental share gains, higher drive density, and improved gross margins.</p>
<p>The analyst raised the CY25 EPS estimate to $8.85 (from $8.60; vs. consensus of $8.06) and reiterated the CY26 EPS estimate at $11.00 (vs. street view of $9.82).</p>
<p>Investors can gain exposure to the stock via&nbsp;<strong>StockSnips AI-Powered Sentiment US All Cap ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWZ#NASDAQ">NEWZ</a>) and&nbsp;<strong>Affinity World Leaders Equity ETF</strong> (BATS:<a class="ticker" href="https://www.benzinga.com/stock/WLDR#BATS">WLDR</a>).</p>
<p><strong>Price Action</strong>: STX shares are up 7.97% at $109.32  at the last check Wednesday.</p>
<p><strong>Read Next</strong>:</p>
<ul>
<li><strong><a href="https://www.benzinga.com//node/43135328" target="_blank" rel="noreferrer noopener">SLB Teams Up With Star Energy Geothermal To Advance Geothermal Tech: Details</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


Analyst Color

Equities

Large Cap

Price Target

Reiteration

Analyst Ratings

NEWZ

WLDR

Seagate Reports Solid Q2, Analyst Optimistic About Advanced HAMR Technology Impact In 2025

<p>Hawthorn Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWBK#NASDAQ">HWBK</a>) reported quarterly earnings of $0.66 per share. This is a 162.86 percent increase over losses of $(1.05) per share from the same period last year.</p>


Earnings

HWBK

Hawthorn Bancshares Q4 EPS $0.66 Up From $(1.05) YoY

Telix Pharmaceuticals shares are trading higher after the company announced it will buy the therapeutic pipeline, technology platform, and research facility from ImaginAb.

<p>Ratings for Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $20.88, a high estimate of $26.00, and a low estimate of $15.00. This upward trend is evident, with the current average reflecting a 13.29% increase from the previous average price target of $18.43.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737572462_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Unity Software among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Andrew Uerkwitz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Underperform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Sell</td>
<td>$15.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Unity Software. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Unity Software compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Unity Software's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/U/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Unity Software analyst ratings.</strong></a></p>
<h2>Delving into Unity Software's Background</h2>
<p>Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.</p>
<h3>Key Indicators: Unity Software's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Unity Software's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-17.95%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Unity Software's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-27.94%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Unity Software's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-3.92%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Unity Software's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-1.86%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.7</strong>, Unity Software faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Unity Software: Insights From 8 Financial Analysts

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Polaris</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with PII, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for Polaris.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 25% bullish and 62%, bearish.</p>
<p>Out of all of the options we uncovered, 7 are puts, for a total amount of $462,535, and there was 1 call, for a total amount of $46,102.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $40.0 to $60.0 for Polaris during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Polaris's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Polaris's substantial trades, within a strike price spectrum from $40.0 to $60.0 over the preceding 30 days.</p>
<h3>Polaris 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737572454_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PII</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.8</td>
<td>$1.65</td>
<td>$1.8</td>
<td>$50.00</td>
<td>$180.0K</td>
<td>4.1K</td>
<td>1.9K</td>
</tr>
<tr>
<td>PII</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.9</td>
<td>$1.8</td>
<td>$1.8</td>
<td>$50.00</td>
<td>$86.2K</td>
<td>4.1K</td>
<td>2.4K</td>
</tr>
<tr>
<td>PII</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.95</td>
<td>$1.75</td>
<td>$1.9</td>
<td>$50.00</td>
<td>$48.6K</td>
<td>4.1K</td>
<td>3.0K</td>
</tr>
<tr>
<td>PII</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.8</td>
<td>$6.2</td>
<td>$6.23</td>
<td>$60.00</td>
<td>$46.1K</td>
<td>1.0K</td>
<td>74</td>
</tr>
<tr>
<td>PII</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.9</td>
<td>$1.75</td>
<td>$1.9</td>
<td>$50.00</td>
<td>$44.2K</td>
<td>4.1K</td>
<td>2.7K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Polaris</h3>
<p>Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products retailed through more than 2,500 dealers in North America and through 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.</p>
<p>Having examined the options trading patterns of Polaris, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Polaris's Current Market Status</h3>
<ul>
<li>Trading volume stands at 820,270, with PII's price down by -1.58%, positioned at $54.17.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 6 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Polaris, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Unpacking the Latest Options Trading Trends in Polaris

<p>In the preceding three months, 16 analysts have released ratings for Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.69, a high estimate of $20.00, and a low estimate of $11.00. A 5.23% drop is evident in the current average compared to the previous average price target of $15.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737572454_0_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of Rivian Automotive's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Mark Delaney</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rivian Automotive. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rivian Automotive compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Rivian Automotive's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Rivian Automotive's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RIVN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Rivian Automotive analyst ratings.</strong></a></p>
<h2>Get to Know Rivian Automotive Better</h2>
<p>Rivian Automotive Inc designs, develops, and manufactures category-defining electric vehicles and accessories. In the consumer market, the company launched the R1 platform with the first generation of consumer vehicles: the R1T, a two-row, five-passenger pickup truck, and the R1S, a three-row, seven-passenger sport utility vehicle (SUV).</p>
<h3>Rivian Automotive: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Rivian Automotive faced challenges, resulting in a decline of approximately <strong>-34.63%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Rivian Automotive's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-125.86%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Rivian Automotive's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-17.3%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Rivian Automotive's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-7.43%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Rivian Automotive's debt-to-equity ratio surpasses industry norms, standing at <strong>1.06</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RIVN

Rivian Automotive Stock: A Deep Dive Into Analyst Perspectives (16 Ratings)

<p>Deep-pocketed investors have adopted a bearish approach towards Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TGT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Target. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable options, 5 are puts, totaling $308,435, and 7 are calls, amounting to $855,990.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $165.0 for Target over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Target's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Target's significant trades, within a strike price range of $120.0 to $165.0, over the past month.</p>
<h3>Target Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737572448_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TGT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$8.85</td>
<td>$8.7</td>
<td>$8.85</td>
<td>$150.00</td>
<td>$620.3K</td>
<td>1.2K</td>
<td align="right">701</td>
</tr>
<tr>
<td>TGT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$8.35</td>
<td>$8.1</td>
<td>$8.4</td>
<td>$130.00</td>
<td>$126.0K</td>
<td>537</td>
<td align="right">150</td>
</tr>
<tr>
<td>TGT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.65</td>
<td>$8.55</td>
<td>$8.55</td>
<td>$120.00</td>
<td>$60.7K</td>
<td>4.9K</td>
<td align="right">72</td>
</tr>
<tr>
<td>TGT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$2.82</td>
<td>$2.78</td>
<td>$2.82</td>
<td>$125.00</td>
<td>$56.4K</td>
<td>1.3K</td>
<td align="right">163</td>
</tr>
<tr>
<td>TGT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$11.9</td>
<td>$11.75</td>
<td>$11.75</td>
<td>$150.00</td>
<td>$52.8K</td>
<td>2.4K</td>
<td align="right">61</td>
</tr>
</tbody>
</table>
</p>
<h3>About Target</h3>
<p>Target serves as the nation's seventh-largest retailer, with its strategy predicated on delivering a gratifying in-store shopping experience and a wide product assortment of trendy apparel, home goods, and household essentials at competitive prices. Target's upscale and stylish image began to carry national merit in the 1990s—a decade in which the brand saw its top line grow threefold to almost $30 billion—and has since cemented itself as a leading US retailer.Today, Target operates over 1,950 stores in the United States, generates over $100 billion in sales, and fulfills over 2 billion customer orders annually. The firm's vast footprint is typically concentrated in urban and suburban markets as the firm seeks to attract a more affluent consumer base.</p>
<p>In light of the recent options history for Target, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Target</h3>
<ul>
<li>With a trading volume of 1,623,019, the price of TGT is down by -0.6%, reaching $136.52.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 41 days from now.</li>
</ul>
<h3>What The Experts Say On Target</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $143.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Target, targeting a price of $134.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Target with a target price of $133.<br />
&#x2A; Consistent in their evaluation, an analyst from Telsey Advisory Group keeps a Outperform rating on Target with a target price of $150.<br />
&#x2A; An analyst from Guggenheim persists with their Buy rating on Target, maintaining a target price of $155. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Target, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


A Closer Look at Target's Options Market Dynamics

<p>Analysts' ratings for Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $176.6, a high estimate of $202.00, and a low estimate of $147.00. This current average has increased by 19.12% from the previous average price target of $148.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737572444_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Vistra by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$191.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$202.00</td>
<td>-</td>
</tr>
<tr>
<td>William Appicelli</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$174.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$169.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$147.00</td>
<td>$146.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Vistra. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vistra compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Vistra's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Vistra's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VST/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Vistra analyst ratings.</strong></a></p>
<h2>Get to Know Vistra Better</h2>
<p>Vistra Energy is one of the largest power producers and retail energy providers in the us Following the 2024 Energy Harbor acquisition, Vistra owns 41 gigawatts of nuclear, coal, natural gas, and solar power generation along with one of the largest utility-scale battery projects in the world. Its retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016. It acquired Dynegy in 2018.</p>
<h3>Breaking Down Vistra's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Vistra's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>53.89%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Utilities sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>29.26%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Vistra's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>60.51%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>4.78%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>5.33</strong>, Vistra faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Vistra: 5 Analysts Share Their Views

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Walt Disney</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DIS, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 25 uncommon options trades for Walt Disney.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 48% bullish and 40%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $347,879, and 21 are calls, for a total amount of $993,788.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $75.0 and $135.0 for Walt Disney, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Walt Disney options trades today is 3649.41 with a total volume of 6,392.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Walt Disney's big money trades within a strike price range of $75.0 to $135.0 over the last 30 days.</p>
<h3>Walt Disney Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737572442_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$27.4</td>
<td>$26.9</td>
<td>$27.4</td>
<td>$95.00</td>
<td>$174.8K</td>
<td>1.5K</td>
<td>64</td>
</tr>
<tr>
<td>DIS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$26.95</td>
<td>$26.85</td>
<td>$26.85</td>
<td>$135.00</td>
<td>$166.2K</td>
<td>205</td>
<td>64</td>
</tr>
<tr>
<td>DIS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$1.4</td>
<td>$0.99</td>
<td>$1.15</td>
<td>$85.00</td>
<td>$115.0K</td>
<td>2.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>DIS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$22.5</td>
<td>$21.85</td>
<td>$21.9</td>
<td>$105.00</td>
<td>$98.5K</td>
<td>308</td>
<td>46</td>
</tr>
<tr>
<td>DIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.25</td>
<td>$10.05</td>
<td>$10.09</td>
<td>$115.00</td>
<td>$58.5K</td>
<td>5.0K</td>
<td>60</td>
</tr>
</tbody>
</table>
</p>
<h3>About Walt Disney</h3>
<p>Disney operates in three global business segments: entertainment, sports, and experiences. Entertainment and experiences both benefit from the firm's ownership of iconic franchises and characters. Entertainment includes the ABC broadcast network, several cable television networks, and the Disney+ and Hulu streaming services. Within the segment, Disney also engages in movie and television production and distribution, with content licensed to movie theaters, other content providers, or, increasingly, kept in-house for use on Disney's own streaming platform and television networks. The sports segment houses ESPN and the ESPN+ streaming service. Experiences contains Disney's theme parks and vacation destinations, and also benefits from merchandise licensing.</p>
<p>Having examined the options trading patterns of Walt Disney, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Walt Disney</h3>
<ul>
<li>With a trading volume of 4,433,466, the price of DIS is up by 0.27%, reaching $108.99.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 14 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Walt Disney</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $127.33333333333333.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Buy with a new price target of $125.<br />
&#x2A; An analyst from Macquarie persists with their Neutral rating on Walt Disney, maintaining a target price of $110.<br />
&#x2A; In a positive move, an analyst from Redburn Atlantic has upgraded their rating to Buy and adjusted the price target to $147. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Walt Disney options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Walt Disney's Options: A Look at What the Big Money is Thinking

<p>Analysts' ratings for Peoples Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEBO#NASDAQ">PEBO</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $38.38, a high estimate of $40.00, and a low estimate of $36.00. This upward trend is evident, with the current average reflecting a 2.02% increase from the previous average price target of $37.62.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737572437_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Peoples Bancorp by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$37.50</td>
<td>$37.50</td>
</tr>
<tr>
<td>Nathan Race</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Manuel Navas</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Timothy Switzer</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Peoples Bancorp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Peoples Bancorp compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Peoples Bancorp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Peoples Bancorp's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PEBO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Peoples Bancorp analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Peoples Bancorp Better</h2>
<p>Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The firm also offers telephone and internet-based banking through both personal computers and mobile devices.</p>
<h3>Peoples Bancorp: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Peoples Bancorp faced challenges, resulting in a decline of approximately <strong>-2.29%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Peoples Bancorp's net margin excels beyond industry benchmarks, reaching <strong>28.17%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Peoples Bancorp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.85%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Peoples Bancorp's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.34%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Peoples Bancorp's debt-to-equity ratio is below the industry average. With a ratio of <b>0.21</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PEBO

Where Peoples Bancorp Stands With Analysts

<p>Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $38.8, a high estimate of $43.00, and a low estimate of $31.00. Highlighting a 4.43% decrease, the current average has fallen from the previous average price target of $40.60. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737572425_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of BorgWarner among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Edison Yu</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$39.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BorgWarner. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BorgWarner compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of BorgWarner's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of BorgWarner's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BWA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on BorgWarner analyst ratings.</strong></a></p>
<h2>Get to Know BorgWarner Better</h2>
<p>BorgWarner is a Tier I auto-parts supplier with three operating segments. The air management group makes turbochargers, e-boosters, e-turbos, timing systems, emissions systems, thermal systems, gasoline ignition technology, powertrain sensors, and cabin heaters. The drivetrain and battery systems group produces automatic transmission components, torque management products, battery heaters, battery charging, and battery modules. The e-propulsion segment makes e-motors, power electronics, and software and control modules. The company's largest customers are Ford and Volkswagen at 14% and 11% of 2023 revenue, respectively. Geographically, Europe accounted for 36% of 2023 revenue, while Asia and North America were 34% and 29% apiece.</p>
<h3>BorgWarner: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Negative Revenue Trend:</strong> Examining BorgWarner's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-4.78%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> BorgWarner's net margin is impressive, surpassing industry averages. With a net margin of <strong>6.78%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.82%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.6%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> BorgWarner's debt-to-equity ratio is below the industry average. With a ratio of <b>0.77</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down BorgWarner: 5 Analysts Share Their Views

<p>Analysts' ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $101.91, a high estimate of $140.00, and a low estimate of $48.00. This upward trend is apparent, with the current average reflecting a 3.89% increase from the previous average price target of $98.09.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737572415_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Ultragenyx Pharmaceutical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$102.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$121.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$121.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Ultragenyx Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Ultragenyx Pharmaceutical's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RARE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</strong></a></p>
<h2>Discovering Ultragenyx Pharmaceutical: A Closer Look</h2>
<p>Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.</p>
<h3>Understanding the Numbers: Ultragenyx Pharmaceutical's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Ultragenyx Pharmaceutical displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>42.27%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Ultragenyx Pharmaceutical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-95.71%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ultragenyx Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-34.27%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-8.46%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.1</strong>, Ultragenyx Pharmaceutical adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RARE

Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views

Inmed Pharmaceuticals Inc. ( ($INM) ) has released its Q1 earnings. Here is a breakdown of the information Inmed Pharmaceuticals Inc. presented to ...

InMed Pharmaceuticals Reports Improved Quarterly Earnings

InMed Pharmaceuticals (INM) has released an update. InMed Pharmaceuticals has published a promising study showcasing the anti-inflammatory effects ...

InMed's Study Highlights Cannabinol's Potential in Skincare

InMed Pharmaceuticals ( ($INM) ) has issued an update. InMed Pharmaceuticals has published a study revealing the potential of cannabinol (CBN) as a...

InMed Pharmaceuticals Explores CBN for Skin Disease Treatment

InMed Pharmaceuticals (INM) has released an update. InMed Pharmaceuticals has entered into a Standby Equity Purchase Agreement with Yorkville Advis...

InMed Pharmaceuticals Secures $10 Million Equity Purchase Agreement

InMed Pharmaceuticals (INM) has released an update. InMed Pharmaceuticals announced the results of their 2024 Annual General Meeting, where shareho...

InMed Pharmaceuticals' 2024 AGM Results Announced

17:21 EST InMed Pharmaceuticals (INM) files to sell 3M common shares for holders Published first on TheFly – the ultimate source for real-time, mar...

InMed Pharmaceuticals files to sell 3M common shares for holders

InMed Pharmaceuticals ( ($INM) ) has provided an update. InMed Pharmaceuticals announced positive results from a long-term preclinical study of its...

InMed's INM-901 Shows Promising Results in Preclinical Alzheimer's Study

InMed Pharmaceuticals (INM) announces "positive" results from a long-term in vivo preclinical Alzheimer's Disease study. In the study, INM-901 demo...

InMed announces 'positive' results from in vivo preclinical Alzheimer's study

InMed Pharmaceuticals (INM) announces it has been granted an international Patent Cooperation Treaty, PCT, patent in the first of several jurisdict...

InMed Pharmaceuticals granted an international PCT patent

An update from InMed Pharmaceuticals ( ($INM) ) is now available. InMed Pharmaceuticals has announced the granting of an international Patent Coope...

InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs

Screenshot 2024-08-27 at 5.44.40 PM

Biotech

InMed Demonstrates Encouraging Data For Its Cannabinoid INM-089 In Treating Dry AMD, An Ocular Disease With Rising Patient Numbers As National Population Ages

Comments

InMed Pharmaceuticals

Interés en corto

InMed Pharmaceuticals (NASDAQ:INM) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL